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Patients with lower limb artery stenosis or occlusion (peripheral artery disease; PAD) have been determined 
to be at very high risk of both major adverse cardiovascular events, such as myocardial infarction and stroke, and 
major adverse limb events, such as amputation and requirement for artery surgery.
Effective medical management has been identified as key in reducing this risk; however, this is often poorly 
implemented in clinical practice. Thus, the aim of this narrative review was to summarize the current evidence 
on the medical management of PAD in order to inform clinicians and highlight recommendations for clinical 
practice. International guidelines, randomized controlled trials, and relevant systematic reviews and meta-
analyses have been included in this study. The focus was the management of the key modifiable risk factors to 
mitigate possible adverse events through prescription of anti-platelet and anticoagulation drugs and medications 
to control low-density lipoprotein cholesterol, blood pressure, and diabetes and aid smoking cessation. The 
available evidence from randomized clinical trials provide a strong rationale for the need for holistic medical 
management programs that are effective in achieving uptake of these medical therapies in patients with PAD. In 
conclusion, people with PAD have some of the highest adverse event rates among those with cardiovascular 
diseases. Secondary preventive measures have been proven effective in reducing these adverse events; however, 
they remain to be adequately implemented. Thus, the need for an effective implementation program has emerged 
to reduce adverse events in this patient group.
(myocardial infarction, stroke, or cardiovascular death; 
MACE) and major adverse limb events (peripheral 
revascularization or major amputation; MALE)5, 6). 
The risk of adverse events is particularly high for 
people with chronic limb-threatening ischemia7, 8).
PAD, as diagnosed by ankle-brachial pressure 
index (ABPI) ＜0.9, has been estimated to affect 
nearly 10% of the population worldwide, affecting 
6%, 9%, 12%, and 16% of 50-, 60-, 70-, and 
80-year-olds, respectively1). Given the aging of the 
world population, particularly in developed countries, 
PAD is projected to represent an important cause of 
morbidity and mortality in the future9). The frequency 
of adverse events due to PAD is substantial. Recent 
Background
Peripheral artery disease (PAD) has been defined 
as an atherothrombotic occlusive disease of the lower 
limb arteries estimated to affect over 220 million 
people worldwide1). PAD can lead to leg pain brought 
on by walking, known as intermittent claudication, or 
in severe cases constant pain in the foot, or ischemic 
ulcers or gangrene, collectively known as chronic 
limb-threatening ischemia 2). PAD may also be 
asymptomatic or associated with atypical symptoms 
such as a burning sensation in the leg3). PAD is 
associated with poor health-related quality of life4) and 
a high risk of major adverse cardiovascular events 
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discussed are as follows: preventing thrombus 
formation, lowering low-density lipoprotein 
cholesterol (LDL-c), blood pressure control, blood 
glucose control, and cessation of tobacco smoking. 
Failure to control these risk factors has been found to 
be associated with an increased risk of adverse events. 
For example, high blood pressure (systolic blood 
pressure ＞140) has been associated with increased 
risk of MACE of 1.23 (95% confidence intervals, CI, 
1.00–1.51)11). Diabetes, particularly insulin treated, 
has been associated with increased mortality among 
people with PAD (hazard ratio, HR, 2.94, 95% CI 
1.86–4.66)16). Prescription of a statin has been 
associated with a 30% reduction (HR 0.70, 95% CI 
0.61–0.82) in the incidence of MALE in a previous 
systematic review29). Similarly, having no diabetes and 
the prescription of a statin have been associated with a 
lower risk of major amputation in people with PAD30). 
This review does not focus on the management of the 
leg symptoms of PAD, such as intermittent 
claudication. Readers are referred to previously 
published reviews on exercise therapy and 
revascularization used to treat the leg symptoms of 
PAD31-33).
1. Anti-Platelet and Anti-Coagulant Treatments
1a. Overall Recommendations
Current international PAD guidelines have 
strongly recommended the prescription of an anti-
platelet medication to people with symptomatic PAD 
to prevent MACE2, 26-28). The two anti-platelet 
medications recommended are aspirin (75–325 mg 
daily) or clopidogrel (75 mg daily). The American, 
Asia-Pacific and European guidelines recommend 
either of these drugs27, 28). The global vascular 
guidelines on the management of chronic limb-
threatening ischemia favors the use of clopidogrel2). 
Recent guidelines recommend low-dose rivaroxaban, 
in addition to low-dose aspirin, in patients at high risk 
of events after considering the risk of bleeding.
1b. Summary of Evidence
Several meta-analyses of RCTs have examined 
the risks and benefits of anti-platelet drugs in people 
with PAD34-37). A Cochrane meta-analysis showed that 
an anti-platelet drug compared to placebo, reduced 
all-cause (relative risk, RR, 0.76, 95% CI 0.60–0.98) 
and cardiovascular mortality (RR 0.54, 95% CI 0.32–
0.93) in patients with intermittent claudication34). A 
more recent meta-analysis supports clopidogrel as the 
anti-platelet of choice to limit MACE. The network 
meta-analysis of 49 RCTs involving 34,518 PAD 
patients examined the relative benefits of different 
series report an incidence of MACE of approximately 
25% over 5 years in people referred to hospital with 
PAD10, 11), with outcomes being particularly poor for 
people presenting with chronic limb-threatening 
ischemia, with MACE rates of approximately 10% per 
year7). Mortality rates of approximately 20% within 5 
years of diagnosis have also been reported12). The 
health service costs of managing PAD-related adverse 
events have also been deemed significant 13, 14). 
Multiple clinical trials have highlighted that the 
incidence of MACE is higher in people presenting 
with PAD than those with some other presentations 
of cardiovascular disease such as coronary artery or 
cerebrovascular disease 5, 15). This highlights the 
importance of implementing medical treatments 
effective at improving outcomes in PAD patients5, 15).
The main strategy to reduce MACE and MALE 
is the medical management of atherosclerosis risk 
factors, including appropriate prescription of anti-
platelet and anti-thrombotic drugs; control of lipids, 
blood pressure, and diabetes; and smoking cessation 
where relevant. However, a growing body of published 
literature has demonstrated that the implementation 
of these treatments remains poor due to multiple 
interrelated issues11, 16-20). Firstly, in many countries, 
the medical management of people with PAD is 
managed by a combination of general practitioners 
and vascular surgeons21, 22), who may have not received 
specific and up-to-date training on the medical 
management of atherosclerosis, which has become 
increasingly complex. Furthermore, published 
evidence that these health professionals rely on have 
been limited or have presented conflicting results with 
regard to safe and appropriate targets16, 17, 23-25). Finally, 
current international guidelines that include or are 
focused on PAD do not comprehensively describe how 
to implement the medical management of PAD, since 
they aim to cover all aspects of arterial disease 
diagnosis and management2, 26-28).
There is, therefore, a need for an up-to-date 
review of the rationales and suggested pathways to 
implement optimal medical management of PAD. 
This review focuses on the current evidence from 
randomized controlled trials (RCTs) and meta-
analyses regarding the most appropriate medical 
management of PAD in order to reduce the risk of 
MACE and MALE. The review aimed to guide health 
professionals who manage patients with PAD in 
identifying relevant risk factors and implementing 
appropriate medical therapies. Table 1 briefly 
summarizes the modifiable medical risk factors of 
importance from each key international guideline, 
including specific targets and overall medication 
recommendations where described. The risk factors 
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Table 1. Overall recommendations for medical management of peripheral artery disease by key guideline
Risk factor Asian Pacific Society of 
Atherosclerosis and 
Vascular Diseases28) 
European Society of 
Cardiology27)
Global CLTI2) American College of 
Cardiology & American 
Heart Association26)
Anti-platelet treatments Aspirin alone (75-325mg 
daily) or clopidogrel alone 
(75mg daily) in patients 
with symptomatic PAD.
Antiplatelet therapy is 
recommended in all 
patients with symptomatic 
PAD (no specific 
medications 
recommended).
Treat all patients with 
CLTI with an anti-platelet 
agent; consider 
clopidogrel as the agent of 
choice.
Aspirin alone (75-325mg 
daily) or clopidogrel alone 
(75mg daily) in patients 
with symptomatic PAD. 





Aspirin (100mg daily) 
plus rivaroxaban (2.5mg 






Consider low-dose aspirin 
and rivaroxaban (2.5mg 
twice daily) in patients 
with CLTI.
Anticoagulation should 
not be used in patients 
with PAD to reduce the 
risk of cardiovascular 
ischaemic events.
Control of low density 
lipoprotein
A statin is recommended 
for all patients with PAD.
Statins are recommended 
in all patients with PAD. 
Serum LDL-c should be 
reduced to ＜1.8mmol/L 
or decreased by ≥ 50% if 
initial LDL-c level is 1.8-
3.5mmol/L. 
Use moderate or high 
intensity statin therapy in 
patients with CLTI.
A statin medication is 
indicated for all patients 
with PAD. 
Control of blood pressure Antihypertensive therapy 
for patients with PAD and 
hypertension; ACEI or 
ARB can reduce 
cardiovascular ischemic 
events.
Control blood pressure to 
＜140/90mmHg in PAD 
patients with 
hypertension; ACEI or 
ARB should be considered 
first-line. 
Control systolic blood 
pressure to ＜140mmHg 
and diastolic ＜90mmHg 
in patients with CLTI. 
Antihypertensive therapy 
for all patients with 
hypertension and PAD; 
ACEI or ARB can reduce 
the risk of cardiovascular 
ischaemic events.
Control of diabetes Management should be 
coordinated between a 
healthcare team (no 
specific medication 
recommendations).
Strict glycaemic control is 
recommended in all 
diabetic patients with 
PAD (no specific 
medication 
recommendations).
Control T2DM in CLTI 
patients to ＜7% HbA1c; 
use metformin as primary 
hypoglycaemic agent.
Management should be 
coordinated between a 
healthcare team (no 
specific medication 
recommendations).
Smoking Cessation PAD patients who smoke 
should be advised to quit 
at every visit; assist in 
developing a quit plan 
including 
pharmacotherapy and/or 
referral to a smoking 
cessation program. 
Patients should avoid 
exposure to environmental 
tobacco smoke.
Smoking cessation is 
recommended for all PAD 
patients. No specific 
medications or other 
interventions provided. 
Offer smoking cessation 
interventions 
(pharmacotherapy, 
counselling, or behaviour 
modification therapy) to 
all patients with CLTI. 
Ask smokers and former 
smokers about status of 
tobacco use at every visit.
PAD patients who smoke 
should be advised to quit 
at every visit; assist in 
developing a quit plan 
including 
pharmacotherapy and/or 
referral to a smoking 
cessation program. 
Patients should avoid 
exposure to environmental 
tobacco smoke.
ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin-2 receptor blocker; CLTI: chronic limb-threatening ischemia; HbA1c: 
haemoglobin A1c (glycated haemoglobin); LDL-c: low-density lipoprotein-c; PAD: peripheral artery disease; T2DM: type-2 diabetes mellitus
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same combination compared with aspirin alone 
reduced the incidence of acute limb ischemia, major 
amputation from vascular causes, myocardial 
infarction, ischemic stroke, or death from 
cardiovascular causes in 6,564 people recently having 
peripheral revascularization40). People given aspirin 
and rivaroxaban had a significant reduction in the 
primary end-point (HR 0.85, 95% CI, 0.76, 0.96), 
with an increased risk of major bleeding (HR 1.42, 
95% CI 1.10, 1.84).
Overall, these trials provide evidence that low-
dose rivaroxaban plus low-dose aspirin is superior to 
aspirin alone in reducing the risk of MACE and 
MALE among people with PAD, but with increased 
risk of major bleeding. As a result, recent guidelines 
have weakly recommended that low-dose rivaroxaban 
plus low dose-aspirin may be considered to reduce 
MACE and MALE in people with symptomatic PAD, 
having considered the associated risk of bleeding28). 
Whether rivaroxaban and aspirin are superior to 
clopidogrel alone remains undetermined.
2. Control of Lipids
2a. Overall Recommendations
Current PAD guidelines strongly recommend the 
prescription of statin in all PAD patients, although 
there is a lack of clarity on the exact statin choice and 
other agent choice if statins are not tolerated or 
contraindicated2, 26-28). Some guidelines focus on 
LDL-c targets rather than recommending specific 
agents, as there is no evidence on ezetimibe in PAD 
and limited but increasing evidence on the 
effectiveness of proprotein convertase subtilisin/kexin 
type 9 (PCSK9) inhibitors. The recent European 
Society of Cardiology and European Atherosclerosis 
Society guidelines suggest people with PAD should 
receive the maximum tolerated dose of a statin, plus 
ezetimibe, or a PCSK9 inhibitor43).
These guidelines also indicate that all people 
with PAD should be considered at very high risk of 
MACE; thus, treatment should target a LDL-c ＜1.4 
mmol/L, which is more intensive than targets 
recommended in PAD-focused guidelines2, 26-28, 43). 
The likely benefit of LDL-c-lowering treatments, as 
with other medical management interventions, 
depends on absolute risk. While all people with PAD 
have a substantial risk of MACE and MALE, this is 
particularly high for some groups, such as people with 
chronic limb-threatening ischemia, or evidence of 
more severe peripheral ischemia or physical 
impairment2, 7, 44-46). None of the PAD guidelines 
provide recommendations for treatments to lower 
triglycerides.
anti-platelets35). It was reported that aspirin was not 
effective at reducing MACE compared to placebo35), 
while clopidogrel did (RR 0.72; 95% CI 0.58–0.91, 
number needed to treat, NNT, 80). Clopidogrel also 
showed the most favorable benefit-harm profile (79% 
cumulative rank probability best and 77% cumulative 
rank probability safest) 35). These findings were 
consistent with an earlier conventional smaller meta-
analysis, which reported that aspirin did not 
significantly reduce MACE but did reduce the risk of 
nonfatal stroke (RR 0.64, 95% CI 0.42–0.99)36). The 
preference for clopidogrel is also supported by the 
CAPRIE trial37), which reported that from 6,452 
patients that had PAD, there was an RR reduction in 
events of 23.8% (95% CI 8.9, 36.2) in those 
administered with clopidogrel (75 mg daily) compared 
to aspirin (325 mg daily)37).
Another consideration is the benefit of anti-
platelet medications on the patency of lower limb 
endovascular or open surgical revascularization 
performed in people with PAD. In the network meta-
analysis discussed above, dual anti-platelet therapy 
with clopidogrel plus aspirin significantly reduced 
major amputations following leg revascularization 
compared to aspirin alone (RR 0.68; 95% CI 0.46, 
0.99, NNT 94), though the risk of severe bleeding 
was determined to be significantly higher (RR 1.48; 
95% CI 1.05, 2.10, number needed to harm 215)35). 
This has led to a weak recommendation in current 
guidelines that dual anti-platelet therapy (clopidogrel 
and aspirin) may reduce the risk of limb-related events 
after lower extremity revascularization for up to 6 
months2, 27, 28).
There have been few trials of warfarin in people 
with PAD undergoing peripheral revascularization; 
overall, these have not provided convincing evidence 
of benefit, and current guidelines recommend against 
its use to reduce MACE and MALE in people with 
PAD2, 26-28, 38). Two recent trials have tested the benefit 
of low-dose rivaroxaban (2.5 mg twice daily) plus 
aspirin (100 mg daily) in people with PAD39-42). The 
COMPASS trial tested whether this combination 
reduced the risk of MACE compared with low-dose 
aspirin alone41). Among 6,391 patients with PAD, the 
combination significantly reduced the risk of MALE 
(HR 0.57, 95% CI 0.37, 0.88) and major amputation 
(HR 0.33, 95% CI 0.12, 0.92), although major 
bleeding was more common (HR 1.61, 95% CI 1.09, 
2.36)39). Combination therapy also significantly 
reduced the risk of MACE compared to aspirin alone, 
although this was reported for a larger group of 
vascular disease patients including those with carotid 
artery disease (HR 0.72, 95% CI 0.57, 0.90)42). 
Meanwhile, the VOYAGER PAD trial tested if the 
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inhibitors or angiotensin receptor blockers26, 28). Some 
guidelines recommend a blood pressure target of less 
than 140/90 mmHg2, 27).
3b. Summary of Evidence
Depending on the definition and study entry 
criteria, between 38 and 86% of people with PAD 
have been determined to have hypertension17). The 
HOPE study is the only large trial that has examined 
whether a medication for hypertension reduces MACE 
in people with PAD, which included 1,715 people 
with symptomatic PAD52). Randomization to a 2.5 
mg dose of ramipril was found to reduce the risk of 
MACE, in comparison to placebo (HR 0.75, 95% CI 
0.61, 0.92)52). In contrast, the SPRINT trial reported 
that among a group 9,361 people with blood pressure 
≥ 130 mmHg, including some participants with PAD, 
intensive blood pressure lowering aimed to achieve 
systolic blood pressure ＜120 mmHg significantly 
reduced vascular events (myocardial infarction, acute 
coronary syndrome, stroke, heart failure, or 
cardiovascular death: HR 0.75, 95% CI 0.64, 0.89) 
and all-cause mortality (HR 0.73, 95% CI 0.60, 
0.90)24). The trial excluded people with diabetes and 
reported a significantly increased rate of serious 
adverse events believed to be related to intensive blood 
pressure lowering24). To the best of our knowledge, the 
trial has not separately reported the results for the 
participants with PAD. One observational study 
reported an increased rate of MACE in PAD patients 
with systolic blood pressure ＜120 mmHg 11). 
Furthermore, the ACCORD trial reported that 
intensive blood pressure lowering in people with 
diabetes did not significantly reduce MACE (HR 0.88, 
95% CI 0.73, 1.06) or all-cause mortality (HR 1.07, 
95% CI 0.85, 1.35)25). As a result, further evidence is 
needed before intensive lowering of blood pressure can 
be recommended for people with PAD.
4. Control of Diabetes
4a. Overall Recommendations
Most current diabetes treatments have not been 
tested in RCTs in people with PAD. Current PAD 
guidelines have emphasized the importance of glucose 
control in people with diabetes and PAD, although 
they do not have clear recommendation of how to 
achieve this28). In the absence of clear evidence, it is 
appropriate to use national and international 
guidelines for the management of diabetes. These 
guidelines recommend an algorithm of management 
to achieve the desired HbA1c target, which is usually 
＜7%53). Metformin is recommended as the first-line 
treatment unless contraindicated or not tolerated. 
2b. Summary of Evidence
Two previous RCTs have tested the benefit of 
treatments to lower LDL-c among people with PAD15, 47). 
The UK Heart Protection Study randomized 6,748 
people with PAD or abdominal aortic aneurysm to 
simvastatin 40 mg or placebo15). Simvastatin led to an 
average lower LDL-c of 1 mmol/L compared to 
placebo, resulting in a significant reduction in major 
vascular events (HR 0.78, 95% CI 0.71, 0.85)15) and 
peripheral revascularization events, but not 
amputations15). None of the other large statin trials 
have reported findings restricted to people with 
PAD48).
The FOURIER trial tested the PCSK9 inhibitor 
evolocumab in 3,642 people with PAD 47). 
Evolocumab significantly reduced median LDL-c by 
about 1.6 mmol/L and the risk of MACE (HR 0.73, 
95% CI 0.59, 0.91) and MALE (HR 0.58, 95% CI 
0.38, 0.88)47). No increase in adverse events in 
participants administered with evolocumab was 
reported. There is current debate on whether PCSK9 
inhibitors are a cost-effective therapy given the 
significant cost associated with their use7, 49). A recent 
analysis modeled the effect of a PCSK9 inhibitor, 
using the data from the FOURIER trial, based on the 
incidence of MACE and MALE among a group of 
Australian patients with PAD7). It was estimated that 
intensive LDL-c lowering using a PCSK9 inhibitor 
would lead to an absolute risk reduction in MACE of 
6.1% (95% CI 2.0, 9.3, NNT 16) and MALE of 
13.1% (95% CI 4.1, 20.5, NNT 8) in people with 
chronic limb-threatening ischemia compared to 3.2% 
(95% CI 1.1, 4.8, NNT 32) and 5.3% (1.7, 8.3, 
NNT 19) in people with intermittent claudication7). 
This illustrates the potential advantage of intensive 
management in people at highest risk, such as those 
with chronic limb-threatening ischemia. The JELIS 
trial reported that people with PAD (n=223) 
randomized to eicosapentaenoic acid (EPA) had a 
significant reduction in major coronary events (HR 
0.44, 95% CI 0.19, 0.97)50). The REDUCE-IT trial, 
which included people with PAD, reported that EPA 
significantly reduced the risk of MACE (HR 0.74, 
95% CI 0.65, 0.83)51). These findings suggest that 
there may also be benefit in lowering triglycerides in 
people with PAD.
3. Control of Blood Pressure
3a. Overall Recommendations
Current PAD guidelines strongly recommend 
people with PAD who also suffer from hypertension 
should receive an antihypertensive medication, 
favoring the use of angiotensin-converting enzyme 
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advice tailored to the patient’s degree of readiness to 
quit, use of nonjudgmental communication, 
motivational interviewing techniques, and intensive 
behavior counseling59, 60). Guideline-recommended 
interventions are informed by patient preferences and 
experiences in quitting.
5b. Summary of Evidence
Smoking has been identified as an important risk 
factor for PAD, and over 30% of people referred to 
hospital with PAD are current smokers11, 16, 61). 
Continued smoking is associated with worse 
outcomes, including reduced patency of peripheral 
revascularization62) and increased risk of MACE and 
MALE (combined HR 1.77, 95% CI 1.30, 2.41)63, 64). 
Quitting smoking has been associated with reduced 
mortality and amputation risks65). Previous studies 
suggest that current smokers value programs which 
allow them autonomy, which are delivered by familiar 
counselors with excellent communication skills, and 
which include printed material and safe drugs they 
can access for no or low cost66).
Few RCTs have tested the success of these 
smoking cessation methods in PAD patients67-70). The 
largest trial included 124 smokers with PAD who 
wanted to quit, being randomized to an intensive 
tailored counseling intervention or minimal advice67). 
The intervention consisted of physician-delivered 
advice and smoking cessation counseling focused on 
the link between smoking and PAD, motivational 
interviewing, cognitive behavior counseling to develop 
a quit plan, and provision of drug information to aid 
quitting. A minimum of six sessions over 5 months 
were provided. The control group received verbal 
advice from their physician and a list of available 
smoking cessation programs. At 6 months, 54% of the 
intervention group reported using varenicline to aid 
smoking cessation compared to 31% of the control 
group (p=0.019) and 21% compared to 7% had 
confirmed smoking abstinence (p=0.023)67). The 
findings suggest that a combination of counseling and 
medications, particularly varenicline, can improve 
smoking cessation at 6 months in PAD patients. 
Quitting was, however, ineffective in over three-
quarter of participants, and no long-term outcomes 
were reported.
A more recent randomized trial examined the 
effect of a 5-minute PowerPoint presentation by a 
junior vascular surgeon on the benefits of smoking 
cessation68). The presentation used a gain-framed 
approach to outline the benefits of quitting in terms 
of reducing the risk of cardiovascular, lung, mouth 
and throat complications and provided information 
about the available methods and support to quit 
Second-line treatments include sodium/glucose 
cotransport-2 (SGLT-2) inhibitors, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, sulphonylureas, 
glucagon-like peptide 1 receptor agonists, and 
insulin53).
4b. Summary of Evidence
Depending on the study entry criteria and 
testing, between 14 and 60% of people with PAD 
have been reported to have diabetes17), which is 
associated with increased mortality16). Furthermore, 
poorly controlled diabetes, as estimated by high 
HbA1c concentrations, has been associated with an 
increased risk of MACE, MALE, and all-cause 
mortality in people with PAD54, 55). The ACCORD 
trial reported that intensive glucose control, as 
compared to standard glucose control, significantly 
reduced the risk of lower extremity amputation (HR 
0.69, 95% CI 0.48, 0.99) in participants with 
diabetes56). These findings emphasize the importance 
of tight control of diabetes among people with PAD. 
The novel SGLT-2 inhibitor empagliflozin has recently 
been reported to improve outcomes among people 
with diabetes and PAD in a randomized placebo-
controlled trial57). Among the 1,461 participants with 
PAD and diabetes, empagliflozin was found to reduce 
the risk of cardiovascular death (HR 0.57, 95% CI 
0.37, 0.88) and all-cause mortality (HR 0.62, 95% CI 
0.44, 0.88), with no excess of lower limb 
amputation57).
Meanwhile, the CANVAS trial has reported on 
the effect of another SGLT2 inhibitor (canagliflozin) 
in people with diabetes, but it did not specifically 
report on people with PAD. It was determined that 
canagliflozin reduced MACE (HR 0.86, 95% CI 0.75, 
0.97), but there was also a significant excess of lower 
limb amputations57). Whether the latter is a chance or 
repeatable findings remains unclear, but caution in the 
use of canagliflozin for people with PAD is currently 
warranted. As a result, previous lower limb 
amputation, foot ulcers, and chronic limb-threatening 




Smoking cessation is recommended for all PAD 
patients, with recommended treatments as follows: 
counseling, varenicline (a partial nicotine receptor 
agonist), nicotine replacement therapy, and bupropion 
(a combined nicotine receptor antagonist and 
norepinephrine-dopamine reuptake inhibitor)58-60). 
Recommended counseling approaches include brief 
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discussed above are of great potential value. A limited 
number of clinical trials that have included some 
participants with PAD have examined the effect of 
such interventions.
The BRIDGE Cardiovascular Prevention study 
tested whether a quality improvement intervention 
could improve the prescription of evidence-based 
therapies in 1,619 people with cardiovascular disease 
through a cluster RCT71). The program included case 
management, audit and feedback, decision support 
tools based on current guidelines, and distribution of 
educational materials. Participants in the intervention 
clusters were more likely to receive a prescription of 
evidence-based therapies than those in control clusters 
(odds ratio 2.30; 95% CI 1.14, 4.65) although risk 
factor control was not significantly improved71). 
Another randomized trial tested the benefit of a 
personalized website along with communication with 
a nurse practitioner for education among 330 
participants with coronary, cerebral, or peripheral 
atherosclerosis72). After 1 year, the relative reduction 
in the Framingham risk score was 14% (95% CI 2 to 
25%)72). A currently ongoing trial is examining the 
effect of a nurse-led, person-centered, health-
promoting program among 210 people with 
intermittent claudication that have recently had 
surgical treatment of intermittent claudication73). 
Approaches which have had success in people at risk 
of cardiovascular disease include practice facilitators74), 
community health workers 75), online education 
programs76), and community forums76). Another 
important consideration is whether interventions to 
improve implementation of medical management 
should be provided through in-person consultation or 
can be provided by remote means, such as telehealth. 
A recent systematic review77) suggests that telehealth 
can be effective at improving secondary prevention in 
people with coronary artery disease.
Conclusion
People with PAD have some of the highest 
adverse event rates among those with cardiovascular 
disease. Secondary preventive measures for key 
modifiable risk factors have proven their efficacy, but 
they remain to be adequately implemented in clinical 
practice. Thus, effective implementation programs are 
required to achieve optimal medical management for 




smoking68). The presentation was delivered in an 
outpatient clinic or hospital individually to patients 
on an electronic notebook. The control group did not 
receive the presentation, but both groups received 2 
weeks free nicotine replacement therapy. The trial only 
managed to recruit 59 of the planned 68 (87%) 
participants. At 6 months, 7 (29%) of the intervention 
group and 9 (32%) of the control group had quit 
smoking (p=1.0), whereas 14 (58%) vs. 10 (36%) had 
reportedly reduced their number of cigarettes smoked 
by at least 50% of that reported at entry. None of the 
participants included in this trial were reported to 
have used varenicline.
A cluster RCT examined the effect of very brief 
advice from a physician about smoking cessation, 
prescription of nicotine replacement therapy, and 
referral to telephone-based smoking cessation 
counseling69). Eight vascular centers were randomly 
allocated one by one to the intervention or standard 
care. Centers allocated to the intervention group 
received training in providing the smoking cessation 
approach via two 2-hour-long web-based seminars 
delivered to study site leaders. At 3 months, 23 of 57 
(40%) patients attending the centers trained to 
provide the smoking cessation intervention, and 26 of 
84 (31%) patients attending the control centers had 
quit smoking (p=0.250)69). Finally, a RCT tested a 
program of five counseling sessions over 6 weeks. The 
sessions were based on motivational conversations, 
advice on and free provision of nicotine replacement 
therapy, and education on the benefits of quitting70). 
The control group received limited advice about 
quitting and free nicotine replacement therapy. Only 
32 of the planned 144 (22%) participants were 
recruited. Four patients were excluded shortly after 
randomization since they did not meet entry criteria. 
At 6 weeks, 3 of 11 (27%) patients in the intervention 
group and 3 of 17 (18%) in the control group had 
quit smoking70). Overall these past trials emphasize 
the challenges of assisting people with PAD to quit 
smoking, but provide some evidence that a 
combination of counseling and smoking cessation 
medications, particularly varenicline, can aid quitting.
Integrated Programs of Medical 
Management
Ideally, any intervention to improve healthcare 
should be able to be integrated into existing systems 
to facilitate efficient care. Patients with PAD are 
typically cared for by a combination of primary 
healthcare physicians and vascular specialists. Thus, 
interventions that effectively enable both specialties to 
better implement the optimal medical management 
Golledge and Drovandi
580
cholesterol lowering in people with peripheral artery 
disease. J Vasc Surg, 2020
8) Ko T, Higashitani M, Uemura Y, Utsunomiya M, 
Yamaguchi T, Matsui A, Ozaki S, Tobita K, Kodama T, 
Morita H, Komuro I. Clinical Outcome and Diverse Risk 
Factors for Different Therapeutic Target Locations of 
Peripheral Artery Disease. J Atheroscler Thromb, 2020; 
27: 769-779
9) Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes 
FGR, Rudan I. Global, regional, and national prevalence 
and risk factors for peripheral artery disease in 2015: an 
updated systematic review and analysis. Lancet Glob 
Health, 2019; 7: e1020-e1030
10) Golledge J, Rowbotham S, Velu R, Quigley F, Jenkins J, 
Bourke M, Bourke B, Thanigaimani S, Chan DC, Watts 
GF. Association of Serum Lipoprotein (a) With the 
Requirement for a Peripheral Artery Operation and the 
Incidence of Major Adverse Cardiovascular Events in 
People With Peripheral Artery Disease. J Am Heart Assoc, 
2020; 9: e015355
11) Thomas Manapurathe D, Moxon JV, Krishna SM, 
Rowbotham S, Quigley F, Jenkins J, Bourke M, Bourke B, 
Jones RE, Golledge J. Cohort Study Examining the 
Association Between Blood Pressure and Cardiovascular 
Events in Patients With Peripheral Artery Disease. J Am 
Heart Assoc, 2019; 8: e010748
12) Beckman JA, Jaff MR, Creager MA. The United States 
preventive services task force recommendation statement 
on screening for peripheral arterial disease: more harm 
than benefit? Circulation, 2006; 114: 861-866
13) Hirsch AT, Hartman L, Town RJ, Virnig BA. National 
health care costs of peripheral arterial disease in the 
Medicare population. Vasc Med, 2008; 13: 209-215
14) Malyar N, Fürstenberg T, Wellmann J, Meyborg M, 
Lüders F, Gebauer K, Bunzemeier H, Roeder N, Reinecke 
H. Recent trends in morbidity and in-hospital outcomes 
of in-patients with peripheral arterial disease: a nationwide 
population-based analysis. Eur Heart J, 2013; 34: 2706-
2714
15) Heart Protection Study Collaborative G. Randomized 
trial of the effects of cholesterol-lowering with simvastatin 
on peripheral vascular and other major vascular outcomes 
in 20,536 people with peripheral arterial disease and other 
high-risk conditions. J Vasc Surg, 2007; 45: 645-654
16) Golledge J, Quigley F, Velu R, Walker PJ, Moxon JV. 
Association of impaired fasting glucose, diabetes and their 
management with the presentation and outcome of 
peripheral artery disease: a cohort study. Cardiovasc 
Diabetol, 2014; 13: 147
17) Nastasi DR, Smith JR, Moxon JV, Trollope A, J. G. 
Prescription of Pharmacotherapy and the Incidence of 
Stroke in Patients With Symptoms of Peripheral Artery 
Disease. Stroke, 2018; 49: 2953-2960
18) Reid C, Nelson MR, Shiel L, Chew D, Connor G, 
DeLooze F. Australians at risk: management of 
cardiovascular risk factors in the REACH Registry. Heart 
Lung Circ, 2008; 17: 114-118
19) Haigh KJ, Bingley J, Golledge J, Walker PJ. Barriers to 
screening and diagnosis of peripheral artery disease by 
general practitioners. Vasc Med, 2013; 18: 325-330
20) Green FC, Levison R, Newton DJ, Littleford R, 
Financial Support
Funding from the National Health and Medical 
Research Council (1063476 and 1022752), James 
Cook University, the Townsville Hospital and Health 
Services Study, Education and Research Trust Fund, 
and Queensland Government supported this work. JG 
holds a Practitioner Fellowships from the National 
Health and Medical Research Council (1117061) and 
a Senior Clinical Research Fellowship from the 
Queensland Government, Australia.
Conflict of Interest
The authors declare that they have no conflicts 
of interest.
References
1) Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg 
JO, McDermott MM, Norman PE, Sampson UKA, 
Williams LJ, Mensah GA, Criqui MH. Comparison of 
global estimates of prevalence and risk factors for 
peripheral artery disease in 2000 and 2010: a systematic 
review and analysis. Lancet, 2013; 382: 1329-1340
2) Conte MS, Bradbury AW, Kolh P, White JV, Dick F, 
Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH; 
GVG Writing Group. Global Vascular Guidelines on the 
Management of Chronic Limb-Threatening Ischemia. 
Eur J Vasc Endovasc Surg, 2019; 58: S1-S109
3) McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian 
L, Liao Y, Criqui MH. Leg symptom categories and rates 
of mobility decline in peripheral arterial disease. J Am 
Geriatr Soc, 2010; 58: 1256-1262
4) Issa SM, Hoeks SE, Scholte op Reimer WJ, Van Gestel 
YR, Lenzen MJ, Verhagen HJ, Pedersen SS, Poldermans 
D. Health-related quality of life predicts long-term 
survival in patients with peripheral artery disease. Vasc 
Med, 2010; 15: 163-169
5) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda 
AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis 
BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, 
Sabatine MS. Low-Density Lipoprotein Cholesterol 
Lowering With Evolocumab and Outcomes in Patients 
With Peripheral Artery Disease: Insights From the 
FOURIER Trial (Further Cardiovascular Outcomes 
Research With PCSK9 Inhibition in Subjects With 
Elevated Risk). Circulation, 2018; 137: 338
6) Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager 
MA, Liau CS, Goto S, Röther J, Steg PG, Hirsch AT; 
REACH Registry Investigators. Cardiovascular risk factor 
control and outcomes in peripheral artery disease patients 
in the Reduction of Atherothrombosis for Continued 
Health (REACH) Registry. Atherosclerosis, 2009; 204: 
e86-e92
7) Nastasi DR, Moxon JV, Norman R, Trollope AF, 
Rowbotham S, Quigley F, Jenkins J, Golledge J. The cost 
effectiveness of intensive low density lipoprotein-
Management of Peripheral Artery Disease
581
Delos Santos AA, Llanes EJB, Obrado-Nabablit GM, 
Pestaño NS, Punzalan FE, Tumanan-Mendoza B. Asia-
Pacific Consensus Statement on the Management of 
Peripheral Artery Disease: A Report from the Asian Pacific 
Society of Atherosclerosis and Vascular Disease Asia-
Pacific Peripheral Artery Disease Consensus Statement 
Project Committee. J Atheroscler Thromb, 2020; 28: 
809-907
29) Pastori D, Farcomeni A, Milanese A, Del Sole F, 
Menichelli D, Hiatt WR, Violi F. Statins and major 
adverse limb events in patients with peripheral artery 
disease: a systematic review and meta-analyssi. Thromb 
Haemost, 2020; 120: 866-875
30) Long CA, Mulder H, Fowkes FGR, Baumgartner I, 
Berger JS, Katona BG, Mahaffey KW, Norgren L, 
Blomster JI, Rockhold FW, Hiatt WR, Patel MR, Jones 
WS, Nehler MR. Incidence and Factors Associated With 
Major Amputation in Patients With Peripheral Artery 
Disease: Insights From the EUCLID Trial. Circ, 2020; 
13e006399
31) Harwood AE, Pymer S, Ingle L, Doherty P, Chetter IC, 
Parmenter B, Askew CD, Tew GA. Exercise training for 
intermittent claudication: a narrative review and summary 
of guidelines for practitioners. BMJ Open Sport Exerc 
Med, 2020; 6: e000897
32) Meneses AL, Ritti-Dias RM, Parmenter B, Golledge J, 
Askew CD. Combined Lower Limb Revascularisation and 
Supervised Exercise Training for Patients with Peripheral 
Arterial Disease: A Systematic Review of Randomised 
Controlled Trials. Sports Med, 2017; 47: 987-1002
33) Golledge J, Singh TP, Alahakoon C, Pinchbeck J, Yip L, 
Moxon JV, Morris DR. Meta-analysis of clinical trials 
examining the benefit of structured home exercise in 
patients with peripheral artery disease. Br J Surg, 2019; 
106: 319-331
34) Wong PF, Chong LY, Mikhailidis DP, Robless P, G. S. 
Antiplatelet agents for intermittent claudication. 
Cochrane Database Syst Rev, 2011; 11: CD001272
35) Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, 
Karunanithy N, Krokidis M, Modarai B, Karnabatidis D. 
Comparative Efficacy and Safety of Different Antiplatelet 
Agents for Prevention of Major Cardiovascular Events and 
Leg Amputations in Patients with Peripheral Arterial 
Disease: A Systematic Review and Network Meta-
Analysis. PLOS One, 2015; 10: e0135692
36) Berger JS, Krantz MJ, Kittelson JM, Hiatt W. Aspirin for 
the prevention of cardiovascular events in patients with 
peripheral artery disease: a meta-analysis of randomized 
trials. JAMA, 2009; 301: 1909-1919
37) CAPRIE Steering Committee. A randomised, blinded, 
trial of clopidogrel versus aspirin in patients at risk of 
ischaemic events (CAPRIE). Lancet, 1996; 348: 1329-
1339
38) Dutch Bypass Oral anticoagulants or Apsirin (BOA) 
Study Group. Efficacy of oral anticoagulants compared 
with aspirin after infrainguinal bypass surgery (The Dutch 
Bypass Oral Anticoagulants or Aspirin Study): a 
randomised trial. Lancet, 2000; 355: 346-351
39) Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, 
Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, 
Verhamme P, Fox KAA, Cook-Bruns N, Lanius V, 
Stonebridge PA, Belch JJ. Detecting diabetes and 
impaired glucose tolerance in patients with atherosclerotic 
peripheral arterial disease. Int Angiol, 2012; 31: 125-128
21) Li B, Salata K, de Mestral C, Hussain MA, Aljabri BA, 
Lindsay TF, Verma S, Al-Omran M. Perceptions of 
Canadian Vascular Surgeons Toward Pharmacologic Risk 
Reduction in Patients with Peripheral Artery Disease: 
2018 Update. Ann Vasc Surg, 2019; 58: 166-173
22) Belch J, Topol EJ, Agnelli G, Bertrand M, Califf RM, 
Clement DL, Creager MA, Easton JD, Gavin JR 3rd, 
Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, 
Smith SC, Sullivan F, Weber MA; Prevention of 
Atherothrombotic Disease Network. Critical issues in 
peripheral arterial disease detection and management: a 
call to action. Arch Intern Med, 2003; 163: 884-892
23) Lane DA, Lip GY. Treatment of hypertension in 
peripheral arterial disease. Cochrane Database Syst Rev, 
2013: CD003075
24) SPRINT Research Group, Wright JT Jr, Williamson JD, 
Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin 
DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, 
Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman 
WC, Cheung AK, Ambrosius WT. A randomized trial of 
intensive versus standard blood‐pressure control. N Engl 
J Med, 2015; 373: 2103-2116
25) ACCORD Study Group, Cushman WC, Evans GW, 
Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, 
Simons-Morton DG, Basile JN, Corson MA, Probstfield 
JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger 
JT, Gerstein HC, Ismail-Beigi F. Effects of intensive 
blood-pressure control in type 2 diabetes mellitus. N Engl 
J Med, 2010; 362: 1575-1585
26) Gerhard-Herman MD, Gornik HL, Barrett C, Barshes 
NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes 
FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, 
Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer 
A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh 
ME. 2016 AHA/ACC Guideline on the Management of 
Patients With Lower Extremity Peripheral Artery Disease: 
A Report of the American College of Cardiology/
American Heart Association Task Force on Clinical 
Practice Guidelines. Circulation, 2017; 135: e726-e779
27) Aboyans V, Ricco JB, Bartelink MEL, Björck M, 
Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo 
M, Debus S, Espinola-Klein C, Kahan T, Kownator S, 
Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, 
Tendera M, Tepe G, Venermo M, Vlachopoulos C, 
Desormais I, Document Reviewers, Widimsky P, Kolh P, 
Agewall S, Bueno H, Coca A, De Borst GJ, Delgado V, 
Dick F, Erol C, Ferrini M, Kakkos S, Katus HA, Knuuti J, 
Lindholt J, Mattle H, Pieniazek P, Piepoli MF, Scheinert 
D, Sievert H, Simpson I, Sulzenko J, Tamargo J, 
Tokgozoglu L, Torbicki A, Tsakountakis N, Tuñón J, Vega 
de Ceniga M, Windecker S, Zamorano JL. Editor’s 
Choice - 2017 ESC Guidelines on the Diagnosis and 
Treatment of Peripheral Arterial Diseases, in collaboration 
with the European Society for Vascular Surgery (ESVS). 
Eur J Vasc Endovasc Surg, 2018; 55: 305-368
28) Abola MTB, Golledge J, Miyata T, Rha SW, Yan BP, Dy 
TC, Ganzon MSV, Handa PK, Harris S, Zhisheng J, 
Pinjala R, Robless PA, Yokoi H, Alajar EB, Bermudez-
Golledge and Drovandi
582
AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis 
BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, 
Sabatine MS. Low-Density Lipoprotein Cholesterol 
Lowering With Evolocumab and Outcomes in Patients 
With Peripheral Artery Disease: Insights From the 
FOURIER Trial (Further Cardiovascular Outcomes 
Research With PCSK9 Inhibition in Subjects With 
Elevated Risk). Circulation, 2018; 137: 338-350
48) Golledge J, Ward NC, GF. W. Lipid management in 
people with peripheral artery disease. Curr Opin Lipidol, 
2019
49) Kumar R, Tonkin A, Liew D, E. Z. The cost-effectiveness 
of PCSK9 inhibitors - The Australian healthcare 
perspective. Int J Cardiol, 2018; 267: 183-187
50) Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa 
H, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, 
Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, 
Matsuzawa Y; JELIS Investigators. Preventive effects of 
eicosapentaenoic acid on coronary artery disease in 
patients with peripheral artery disease. Circ J, 2010; 74: 
1451-1457
51) Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, 
Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz 
C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. 
Cardiovascular Risk Reduction with Icosapent Ethyl for 
Hypertriglyceridemia. N Engl J Med, 2019; 380: 11-22
52) Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, 
Qilong Y, Yusuf S; HOPE study investigators. Impact of 
ramipril in patients with evidence of clinical or subclinical 
peripheral arterial disease. Eur Heart J, 2004; 25: 17-24
53) Ltd. TRACoGP. The Royal Australian College of General 
Practitioners. Management of type 2 diabetes: A 
handbook for general practice. East Melbourne, Vic: 
RACG. 2020
54) Singh N, Zeng C, Lewinger JP, Wolfson AM, Shavelle D, 
Weaver F, Garg PK. Preoperative hemoglobin A1c levels 
and increased risk of adverse limb events in diabetic 
patients undergoing infrainguinal lower extremity bypass 
surgery in the Vascular Quality Initiative. J Vasc Surg, 
2019; 70: 1225-1234
55) Low Wang CC, Blomster JI, Heizer G, Berger JS, 
Baumgartner I, Fowkes FGR, Held P, Katona BG, 
Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold 
FW, Mahaffey KW, Patel MR, Hiatt WR; EUCLID Trial 
Executive Committee and Investigators. Cardiovascular 
and Limb Outcomes in Patients With Diabetes and 
Peripheral Artery Disease: The EUCLID Trial. J Am Coll 
Cardiol, 2018; 72: 3274-3284
56) Goldman MP, Clark CJ, Craven TE, Davis RP, Williams 
TK, Velazquez-Ramirez G, Hurie JB, Edwards MS. Effect 
of Intensive Glycemic Control on Risk of Lower 
Extremity Amputation. J Am Coll Surg, 2018; 227: 596-
604
57) Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett 
D, Hehnke U, George JT, Zinman B. Cardiovascular 
Outcomes and Safety of Empagliflozin in Patients With 
Type 2 Diabetes Mellitus and Peripheral Artery Disease: A 
Subanalysis of EMPA-REG OUTCOME. Circulation, 
2018; 137: 405-407
58) Leone FT, Zhang Y, Evers-Casey S, Evins AE, Eakin MN, 
Fathi J, Fennig K, Folan P, Galiatsatos P, Gogineni H, 
Connolly SJ, Yusuf S. Major Adverse Limb Events and 
Mortality in Patients With Peripheral Artery Disease: The 
COMPASS Trial. J Am Coll Cardiol, 2018; 71: 2306-
2315
40) Bonaca MP, Bauersachs RM, Anand SS, Debus ES, 
Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, 
Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, 
Mátyás L, Krievins DK, Diaz R, Brodmann M, 
Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. 
Rivaroxaban in Peripheral Artery Disease after 
Revascularization. NEJM, 2020; 382: 1994-2004
41) Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart 
RG, Shestakovska O, Diaz R, Alings M, Lonn EM, 
Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, 
Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, 
Maggioni AP, Lopez-Jaramillo P, O’Donnell M, Kakkar 
AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai 
M, Ryden L, Pogosova N, Dans AL, Lanas F, 
Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme 
PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix 
C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, 
Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS 
Investigators. Rivaroxaban with or without Aspirin in 
Stable Cardiovascular Disease. n Engl J Med, 2017; 377: 
1319-1330
42) Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, 
Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, 
Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, 
O’Donnell M, Commerford PJ, Vinereanu D, Pogosova 
N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos 
JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong 
DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS 
Investigators. Rivaroxaban with or without aspirin in 
patients with stable peripheral or carotid artery disease: an 
international, randomised, double-blind, placebo-
controlled trial. Lancet, 2018; 391: 219-229
43) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula 
M, Badimon L, Chapman MJ, De Backer GG, Delgado 
V, Ference BA, Graham IM, Halliday A, Landmesser U, 
Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, 
Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; 
ESC Scientific Document Group. 2019 ESC/EAS 
Guidelines for the management of dyslipidaemias: lipid 
modification to reduce cardiovascular risk. Eur Heart J, 
2020; 41: 111-188
44) Morris DR, Rodriguez AJ, Moxon JV, Cunningham MA, 
McDermott MM, Myers J, Leeper NJ, Jones RE, 
Golledge J. Association of lower extremity performance 
with cardiovascular and all-cause mortality in patients 
with peripheral artery disease: a systematic review and 
meta-analysis. J Am Heart Assoc, 2014; 3: e001105
45) Morris DR, Singh TP, Moxon JV, Smith A, Stewart F, 
Jones RE, Golledge J. Assessment and validation of a 
novel angiographic scoring system for peripheral artery 
disease. Br J Surg, 2017; 104: 544-554
46) Morris DR, Skalina TA, Singh TP, Moxon JV, Golledge J. 
Association of Computed Tomographic Leg Muscle 
Characteristics With Lower Limb and Cardiovascular 
Events in Patients With Peripheral Artery Disease. J Am 
Heart Assoc, 2018; 7: e009943
47) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda 
Management of Peripheral Artery Disease
583
Schanzer A, Tan TW, Beck AW, Hallett JH, MacKenzie 
TA, Edelen MO, Hoel AW, Rigotti NA, Farber A. 
Feasibility and pilot efficacy of a brief smoking cessation 
intervention delivered by vascular surgeons in the Vascular 
Physician Offer and Report (VAPOR) Trial. J Vasc Surg, 
2017; 65: 1152-1160.e2
70) Kehlet M, Heeseman S, Tønnesen H, TV. S. Perioperative 
smoking cessation in vascular surgery: challenges with a 
randomized controlled trial. Trials, 2015; 16: 441
71) Machline-Carrion MJ, Soares RM, Damiani LP, Campos 
VB, Sampaio B, Fonseca FH, Izar MC, Amodeo C, 
Pontes-Neto OM, Santos JY, Gomes SPDC, Saraiva JFK, 
Ramacciotti E, Barros E Silva PGM, Lopes RD, Brandão 
da Silva N, Guimarães HP, Piegas L, Stein AT, Berwanger 
O; BRIDGE Cardiovascular Prevention Investigators. 
Effect of a Multifaceted Quality Improvement 
Intervention on the Prescription of Evidence-Based 
Treatment in Patients at High Cardiovascular Risk in 
Brazil: The BRIDGE Cardiovascular Prevention Cluster 
Randomized Clinical Trial. JAMA Cardiol, 2019; 4: 408-
417
72) Vernooij JW, Kaasjager HA, van der Graaf Y, Wierdsma J, 
Grandjean HM, Hovens MM, de Wit GA, Visseren FL; 
SMARTStudy Group. Internet based vascular risk factor 
management for patients with clinically manifest vascular 
disease: randomised controlled trial. BMJ, 2012; 344: 
e3750
73) Haile S, Linné A, Johansson UB, E. J-A. Follow-up after 
surgical treatment for intermittent claudication 
(FASTIC): a study protocol for a multicentre randomised 
controlled clinical trial. BMC Nurs, 2020; 19: 45
74) Shelley DR, Gepts T, Siman N, Nguyen AM, Cleland C, 
Cuthel AM, Rogers ES, Ogedegbe O, Pham-Singer H, 
Wu W, Berry CA. Cardiovascular Disease Guideline 
Adherence: An RCT Using Practice Facilitation. Am J 
Prev Med, 2020; 58: 683-690
75) Joshi R, Agrawal T, Fathima F, Usha T, Thomas T, 
Misquith D, Kalantri S, Chidambaram N, Raj T, 
Singamani A, Hegde S, Xavier D, Devereaux PJ, Pais P, 
Gupta R, Yusuf S. Cardiovascular risk factor reduction by 
community health workers in rural India: A cluster 
randomized trial. Am Heart J, 2019; 216: 9-19
76) Rich-Edwards JW, Stuart JJ, Skurnik G, Roche AT, Tsigas 
E, Fitzmaurice GM, Wilkins-Haug LE, Levkoff SE, Seely 
EW. Randomized Trial to Reduce Cardiovascular Risk in 
Women with Recent Preeclampsia. J Womens Health 
(Larchmt), 2019; 28: 1493-1504
77) Turan Kavradim S, Özer Z Bİ. Effectiveness of telehealth 
interventions as a part of secondary prevention in 
coronary artery disease: a systematic review and meta-
analysis. Scand J Caring Sci, 2020: doi: 10.1111/
scs.12785
Kantrow S, Kathuria H, Lamphere T, Neptune E, Pacheco 
MC, Pakhale S, Prezant D, Sachs DPL, Toll B, Upson D, 
Xiao D, Cruz-Lopes L, Fulone I, Murray RL, O’Brien 
KK, Pavalagantharajah S, Ross S, Zhang Y, Zhu M, 
Farber HJ. Initiating Pharmacologic Treatment in 
Tobacco-Dependent Adults. An Official American 
Thoracic Society Clinical Practice Guideline. Am J Respir 
Crit Care Med, 2020; 202: e5-e31
59) Van Schayck OCP, Williams S, Barchilon V, Baxter N, 
Jawad M, Katsaounou PA, Kirenga BJ, Panaitescu C, 
Tsiligianni IG, Zwar N, Ostrem A. Treating tobacco 
dependence: guidance for primary care on life-saving 
interventions. Position statement of the IPCRG. NPJ 
Prim Care Respir Med, 2017; 27: 38
60) NICE. Stop smoking interventions and services: NICE 
guidelines. In: England PH, editor. 2018
61) Lu L, Mackay DF, JP. P. Meta-analysis of the association 
between cigarette smoking and peripheral arterial disease. 
Heart, 2014; 100: 414-423
62) Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, 
Büller HR, MH. P. Smoking and the patency of lower 
extremity bypass grafts: a meta-analysis. J Vasc Surg, 
2005; 42: 67-74
63) Jonason T, R. B. Cessation of smoking in patients with 
intermittent claudication. Effects on the risk of peripheral 
vascular complications, myocardial infarction and 
mortality. Acta Med Scand, 1987; 221: 253-260
64) Hageman SHJ, de Borst GJ, Dorresteijn JAN, Bots ML, 
Westerink J, Asselbergs FW, Visseren FLJ; UCC-SMART 
Study Group. Cardiovascular risk factors and the risk of 
major adverse limb events in patients with symptomatic 
cardiovascular disease. Heart, 2020: 10.1136/
heartjnl-2019-316088
65) Armstrong EJ, Wu J, Singh GD, Dawson DL, Pevec WC, 
Amsterdam EA, Laird JR. Smoking cessation is associated 
with decreased mortality and improved amputation-free 
survival among patients with symptomatic peripheral 
artery disease. J Vasc Surg, 2014; 60: 1565-1571
66) Katz DA, Hamlin C, Vander Weg MW, Grant KM, 
Stewart Steffensmeier KR, Paez M, Hawley ST, Gaeth G. 
Veterans’ preferences for tobacco treatment in primary 
care: A discrete choice experiment. Patient Educ Couns, 
2020; 103: 652-660
67) Hennrikus D, Joseph AM, Lando HA, Duval S, Ukestad 
L, Kodl M, Hirsch AT. Effectiveness of a smoking 
cessation program for peripheral artery disease patients: a 
randomized controlled trial. J Am Coll Cardiol, 2010; 56: 
2105-2112
68) Rajaee S, Holder T, Indes JE, Muhs B, Sarac T, Sumpio B, 
Toll BA, Ochoa Chaar CI. A Pilot Study of a 
Standardized Smoking Cessation Intervention for Patients 
with Vascular Disease. Ann Vasc Surg, 2019; 61: 91-99.e3
69) Goodney PP, Spangler EL, Newhall K, Brooke BS, 
